Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Thymosin-alpha-1

Thymalfasin, Zadaxin, Thymosin α1

Quick Stats
Studies 759
Trials 63
Score 1
2015 pubmed

Immunogenicity in Swine of Orally Administered Recombinant Lactobacillus plantarum Expressing Classical Swine Fever Virus E2 Protein in Conjunction with Thymosin α-1 as an Adjuvant.

Xu. Yi-Gang YG; Guan. Xue-Ting XT; Liu. Zhong-Mei ZM; Tian. Chang-Yong CY; Cui. Li-Chun LC

Key Findings

  • Oral Lactobacillus expressing CSFV E2 protein triggers IgA, IgG, and T‑cell immunity in pigs
  • Including thymosin‑alpha‑1 as an adjuvant significantly enhances those immune responses
  • The combined probiotic‑vaccine approach is safe and effective in a swine model

Practical Outcomes

  • For hobbyists, the study suggests thymosin‑alpha‑1 can boost mucosal immune responses, but the specific oral probiotic vaccine method isn’t ready for human use. It highlights a potential future direction for oral vaccines, not a current protocol you can apply.

Summary

Scientists made a friendly bacteria that makes a pig virus protein and gave it to pigs by mouth. Adding the immune‑boosting peptide thymosin‑alpha‑1 made the pigs’ immune response stronger than the bacteria alone. This shows the peptide can act as a vaccine helper, but the work was done in pigs, not people, and uses genetic engineering that isn’t practical for everyday use.

Abstract

Classical swine fever, caused by classical swine fever virus (CSFV), is a highly contagious disease that results in enormous economic losses in pig industries. The E2 protein is one of the main structural proteins of CSFV and is capable of inducing CSFV-neutralizing antibodies and cytotoxic T lymphocyte (CTL) activities in vivo. Thymosin α-1 (Tα1), an immune-modifier peptide, plays a very important role in the cellular immune response. In this study, genetically engineered Lactobacillus plantarum bacteria expressing CSFV E2 protein alone (L. plantarum/pYG-E2) and in combination with Tα1 (L. plantarum/pYG-E2-Tα1) were developed, and the immunogenicity of each as an oral vaccine to induce protective immunity against CSFV in pigs was evaluated. The results showed that recombinant L. plantarum/pYG-E2 and L. plantarum/pYG-E2-Tα1 were both able to effectively induce protective immune responses in pigs against CSFV infection by eliciting immunoglobulin A (IgA)-based mucosal, immunoglobulin G (IgG)-based humoral, and CTL-based cellular immune responses via oral vaccination. Significant differences (P < 0.05) in the levels of immune responses were observed between L. plantarum/pYG-E2-Tα1 and L. plantarum/pYG-E2, suggesting a better immunogenicity of L. plantarum/pYG-E2-Tα1 as a result of the Tα1 molecular adjuvant that can enhance immune responsiveness and augment specific lymphocyte functions. Our data suggest that the recombinant Lactobacillus microecological agent expressing CSFV E2 protein combined with Tα1 as an adjuvant provides a promising strategy for vaccine development against CSFV.

Study Information

Provider

pubmed

Year

2015

Date

2015-03-27T00:00:00.000Z

DOI

10.1128/aem.00127-15